1742PDTrilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

Abstract Background Chemotherapy (chemo)-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Current supportive therapies are lineage specific and administered after damage has occurred. T, a highly selective, reversible CDK4/6 inhibitor and first-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser:	Daniel, D, Kuchava, V, Bondarenko, I, Ivashchuk, O, Spigel, D, Dasgupta, A, Reddy, S, Melkadze, T, Jaal, J, Kudaba, I, Hart, L, Matitashvili, A, Koynov, K D, Yang, Z, Wolfe, S G, Malik, R, Morris, S R, Antal, J M, Goldschmidt, J
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!